Impact of homologous recombination repair/BReast CAncer (BRCA) gene alterations on survival in a real-world setting of metastatic prostate cancer.
BReast CAncer (BRCA) gene
metastatic hormone‐sensitive prostate cancer
metastatic prostate cancer
mutation
Journal
BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721
Informations de publication
Date de publication:
10 Jul 2024
10 Jul 2024
Historique:
medline:
10
7
2024
pubmed:
10
7
2024
entrez:
10
7
2024
Statut:
aheadofprint
Résumé
To investigate alterations of homologous recombination repair (HRR) and especially BReast CAncer 1/2 (BRCA1/2) gene on overall survival (OS). Moreover, to explore the effect of inhibition of poly(ADP-ribose)-polymerase (PARPi) as systemic therapy for metastatic castration-resistant prostate cancer (mCRPC). Of all HRR-screened patients with metastatic prostate cancer, baseline characteristics were sampled. Kaplan-Meier estimates and multivariable Cox regression models predicted the effect of HRR/BRCA1/2 alterations on OS. Of 196 eligible patients, 61 (31%) harboured any HRR and 40 (20%) BRCA1/2 alterations. Of HRR alterations, 40 (66%) vs six (10%) vs five (8.2%) vs four (6.6%) vs two (3.3%) vs four (6.6%) were BRCA1/2 vs Ataxia-telangiectasia mutated kinase (ATM) vs checkpoint kinase 2 (CHEK2) vs cyclin-dependent kinase 12 (CDK12) vs Fanconi anaemia complementation Group A (FANCA) vs positive for other mutations. Of these, 30% received a PARPi. OS differed significantly between HRR-positive vs -negative patients. Specifically in hormone-sensitive prostate cancer, the median OS was 63 (HRR positive) vs 57 (BRCA1/2 positive) vs 113 months (HRR negative) (P ≤ 0.01). In mCRPC, OS was 42 (HRR positive) vs 41 (BRCA1/2 positive) vs 70 months (HRR negative) (P ≤ 0.01). HRR and BRCA1/2 alterations were associated with worse OS after multivariable adjustment. Finally, patients with mCRPC with BRCA1/2 mutation treated without PARPi harboured worse OS than patients with BRCA1/2 mutation and PARPi therapy (median OS: 33 vs 48 months, P < 0.03). Incidence of HRR alteration in a clinical real-world setting is high when using blood- and tissue-based tests. Patients with HRR/BRCA alterations have worse outcomes resulting in significant OS differences between HRR/BRCA-positive patients with mCRPC with and without PARPi usage vs HRR/BRCA-negative patients.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). BJU International published by John Wiley & Sons Ltd on behalf of BJU International.
Références
Mori K, Mostafaei H, Sari Motlagh R et al. Systemic therapies for metastatic hormone‐sensitive prostate cancer: network meta‐analysis. BJU Int 2022; 129: 423–433
Wenzel M, Würnschimmel C, Nocera L et al. Overall survival after systemic treatment in high‐volume versus low‐volume metastatic hormone‐sensitive prostate cancer: systematic review and network meta‐analysis. Eur Urol Focus 2022; 8: 399–408
Wenzel M, Garcia CC, Hoeh B et al. Real‐world evidence of outcomes of oligometastatic hormone‐sensitive prostate cancer patients treated with metastasis‐directed therapy. Prostate 2023; 83: 1365–1372
Hoeh B, Garcia CC, Wenzel M et al. Triplet or doublet therapy in metastatic hormone‐sensitive prostate cancer: updated network meta‐analysis stratified by disease volume. Eur Urol Focus 2023; 9: 838–842
Mandel P, Hoeh B, Wenzel M et al. Triplet or doublet therapy in metastatic hormone‐sensitive prostate cancer patients: a systematic review and network meta‐analysis. Eur Urol Focus 2023; 9: 96–105
Wenzel M, Hoeh B, Hurst F et al. Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real‐world setting of metastatic hormone‐sensitive prostate cancer patients. Prostate 2024. Epub ahead of print. https://doi.org/10.1002/pros.24754
Agarwal N, Azad AA, Carles J et al. Talazoparib plus enzalutamide in men with first‐line metastatic castration‐resistant prostate cancer (TALAPRO‐2): a randomised, placebo‐controlled, phase 3 trial. Lancet 2023; 402: 291–303
Saad F, Clarke NW, Oya M et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration‐resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double‐blind, phase 3 trial. Lancet Oncol 2023; 24: 1094–1108
Hussain M, Mateo J, Fizazi K et al. Survival with Olaparib in metastatic castration‐resistant prostate cancer. N Engl J Med 2020; 383: 2345–2357
Chi KN, Sandhu S, Smith MR et al. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration‐resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Ann Oncol 2023; 34: 772–782
Agarwal N, Saad F, Azad AA et al. TALAPRO‐3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration‐sensitive prostate cancer. Future Oncol 2024; 20: 493–505
Sciarra A, Frisenda M, Bevilacqua G et al. How the analysis of the pathogenetic variants of DDR genes will change the management of prostate cancer patients. Int J Mol Sci 2022; 24: 674
Schostak M, Bradbury A, Briganti A et al. Practical guidance on establishing a molecular testing pathway for alterations in homologous recombination repair genes in clinical practice for patients with metastatic prostate cancer. Eur Urol Oncol 2024; 7: 344–354
Olmos D, Lorente D, Alameda D et al. Treatment patterns and outcomes in metastatic castration‐resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes. Ann Oncol 2024; 35: 458–472
Uemura H, Oya M, Kamoto T et al. The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration‐resistant prostate cancer in real‐world clinical practice: the multi‐institutional observational ZENSHIN study. Cancer Med 2023; 12: 5265–5274
Cursano MC, Giunta EF, Scarpi E et al. Impact of somatic DNA repair mutations on the clinical outcomes of bone metastases from castration‐resistant prostate cancer. Int J Mol Sci 2023; 24: 12436
Mandel P, Hoeh B, Humke C et al. Feasibility of next‐generation sequencing of liquid biopsy (circulating tumor DNA) samples and tumor tissue from patients with metastatic prostate cancer in a real‐world clinical setting in Germany. Eur Urol Focus 2024:S2405‐4569(24)00043‐9. https://doi.org/10.1016/j.euf.2024.02.007
Miyake H, Matsushita Y, Watanabe H et al. Prognostic significance of time to castration resistance in patients with metastatic castration‐sensitive prostate cancer. Anticancer Res 2019; 39: 1391–1396
Wenzel M, Preisser F, Hoeh B et al. Impact of time to castration resistance on survival in metastatic hormone sensitive prostate cancer patients in the era of combination therapies. Front Oncol 2021; 11: 659135
Chi KN, Agarwal N, Bjartell A et al. Apalutamide for metastatic, castration‐sensitive prostate cancer. N Engl J Med 2019; 381: 13–24
Davis ID, Martin AJ, Stockler MR et al. Enzalutamide with standard first‐line therapy in metastatic prostate cancer. N Engl J Med 2019; 381: 121–131
Castro E, Goh C, Olmos D et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 2013; 31: 1748–1757
Fizazi K, Tran N, Fein L et al. Abiraterone plus prednisone in metastatic, castration‐sensitive prostate cancer. N Engl J Med 2017; 377: 352–360
Ryan CJ, Smith MR, de Bono JS et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368: 138–148
Li L, Karanika S, Yang G et al. Androgen receptor inhibitor‐induced “BRCAness” and PARP inhibition are synthetically lethal for castration‐resistant prostate cancer. Sci Signal 2017; 10(480): eaam7479
Abbotts R, Dellomo AJ, Rassool FV. Pharmacologic induction of BRCAness in BRCA‐proficient cancers: expanding PARP inhibitor use. Cancers (Basel) 2022; 14: 2640
Castro E, Romero‐Laorden N, Del Pozo A et al. PROREPAIR‐B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration‐resistant prostate cancer. J Clin Oncol 2019; 37: 490–503
Annala M, Struss WJ, Warner EW et al. Treatment outcomes and tumor loss of heterozygosity in germline DNA repair‐deficient prostate cancer. Eur Urol 2017; 72: 34–42
Leith A, Ribbands A, Kim J et al. Real‐world homologous recombination repair mutation testing in metastatic castration‐resistant prostate cancer in the USA, Europe and Japan. Future Oncol 2022; 18: 937–951